A company called Arvinas has shared exciting early results from a small clinical trial testing a new experimental drug called ARV-102 for Parkinson’s disease. The drug works by helping the body break down a specific protein called LRRK2, which is linked to the disease. After 28 days of treatment, the drug successfully reduced LRRK2 levels by more than 50% in the spinal fluid of people with Parkinson’s. The findings were presented at a major medical conference in Copenhagen called the AD/PD 2026. The drug was also shown to lower other harmful substances in the body that are associated with Parkinson’s and a related condition called progressive supranuclear palsy (PSP). Importantly, the drug was well tolerated by patients at all doses tested, which ranged from 20 mg to 80 mg per day. No serious side effects were reported, and any reactions were mild. The drug also proved it could reach the brain, as its levels in spinal fluid increased with higher doses. LRRK2 reduction reached the target level by day 14 and was maintained through day 28. Experts like Dr. Andrew Siderowf, who leads Parkinson’s research, called the results very encouraging and said they suggest a new way to treat Parkinson’s may be on the horizon. The company’s top medical officer, Dr. Noah Berkowitz, added that this is the first time such strong reductions in LRRK2 have been seen with this type of drug, which could open doors for treating other brain diseases. Arvinas plans to start a new study in people with PSP in the middle of 2026, with the possibility of larger trials later this year.